Deals Of The Week Ponders When $2.1 Billion Is A Steal
Executive Summary
M&A can be expensive, but sometimes deals pay huge dividends. Bristol’s $2.1 billion acquisition of Medarex from 2009 looks like it’ll pay for itself many times over. Plus Actavis buys Warner Chilcott, Novo buys Xellia, and Elan and BTG each keep very busy.
You may also be interested in...
MorphoSys: Accelerating The Long Transformation
Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.
Antibiotic Commercial Models Under Revision To Tackle Stewardship Tension
Large pharma companies like AstraZeneca and GSK tout a project to devise new antibiotic development strategies that are independent of sales volumes, while some companies say stewardship and a sales-based system can go hand in hand.
BARDA To Fund Pediatric Development Of Cempra’s Solithromycin
Antibiotic-focused biotech can earn $58 million over five years under the government contract, which provides for testing of the novel macrolide in pediatric indications and for protection against bioterror-threat pathogens.